Literature DB >> 6240460

Deficiency in C3b receptors on neutrophils of patients with chronic granulomatous disease and hyperimmunoglobulin-E recurrent infection (Job's) syndrome.

T A Gaither, J I Gallin, K Iida, V Nussenzweig, M M Frank.   

Abstract

C3b receptor (CR1) expression by neutrophils (PMNs) and erythrocytes (Es) from patients with chronic granulomatous disease (CGD) or with hyper-IgE, frequent infection (Job's) syndrome was compared with that of control subjects. The control subjects consisted of one group of patients with infections and a second group of normal, healthy individuals. Three quantitative assays were used: rosette formation with C3b-coated cellular intermediates (EAC43b), binding of radiolabeled monoclonal anti-CR1 ([125I]anti-CR1) to PMN surfaces, and binding of the antibody to nonidet P-40 (NP-40) extracts of PMNs and Es in an immunoradiometric assay. Rosette formation by the PMNs of five male CGD patients was about 50% of that of paired normal control subjects, whereas the rosette formation of three female CGD patients was similar to that of the control subjects. Surface binding of [125I]anti-CR1 to PMNs of 10 CGD patients was about half that of the normal subjects (mean percent binding was 2.33% for the CGD patients vs. 3.86% for the normal subjects, giving a difference of -1.53 +/- 0.22%, P less than 0.001 by the paired-sample t test). The degree of PMN binding was similarly low for both the male and the female CGD patients. Conversely, the binding of anti-CR1 to the PMNs of 11 infected control patients appeared to be similar to that of the normal subjects (4.51% for the patient vs. 4.21% for the paired normal subjects). The infected control group originally included four Job's syndrome patients, and when this subgroup was analyzed separately, their PMNs were shown to bind significantly less anti-CR1 than did the PMNs of the normal subjects (P less than 0.01 by the paired-sample t test). In contrast, the other infected control patients showed higher-than-normal levels of anti-CR1 binding (P less than 0.05). When compared to that of the normal subjects, the total CR1 quantitated in PMN extracts was also lower than normal in CGD patients (P less than 0.01 and in the PMN extracts of eight Job's syndrome patients tested (P less than 0.01). The PMNs of the other infected control subjects were not significantly different from those of the normal subjects in total CR1 expression. Extracts of Es from Job's syndrome patients also had fewer than normal CR1 (P less than 0.02). On the other hand, CR1 levels in E extracts from the CGD patients and the other control patients were similar to those in the normal control subjects. Quantitations of C3, C4, and factor B were normal in CGD.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6240460     DOI: 10.1007/bf00918218

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  26 in total

1.  Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.

Authors:  D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

2.  Evaluation of opsonic and leukocyte function with a spectrophotometric test in patients with infection and with phagocytic disorders.

Authors:  T P Stossel
Journal:  Blood       Date:  1973-07       Impact factor: 22.113

3.  Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro.

Authors:  R D Diamond; R K Root; J E Bennett
Journal:  J Infect Dis       Date:  1972-04       Impact factor: 5.226

4.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

5.  Stimulation of the intracellular killing of Staphylococcus aureus by monocytes: regulation by immunoglobulin G and complement components C3/C3b and B/Bb.

Authors:  P C Leijh; M T van den Barselaar; M R Daha; R van Furth
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

6.  In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood.

Authors:  P G Quie; J G White; B Holmes; R A Good
Journal:  J Clin Invest       Date:  1967-04       Impact factor: 14.808

7.  Cleavage of membrane-bound C3b and C3bi by viable human neutrophils (PMN).

Authors:  T A Gaither; C H Hammer; J E Gadek; K Katusha; M Santaella; M M Frank
Journal:  Mol Immunol       Date:  1983-06       Impact factor: 4.407

8.  IgA-containing circulating immune complexes in dermatitis herpetiformis, Henoch-Schönlein purpura, systemic lupus erythematosus and other diseases.

Authors:  R P Hall; T J Lawley; J A Heck; S I Katz
Journal:  Clin Exp Immunol       Date:  1980-06       Impact factor: 4.330

9.  Studies in normal and chronic granulomatous disease neutrophils indicate a correlation of tubulin tyrosinolation with the cellular redox state.

Authors:  J Nath; J I Gallin
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

10.  Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte.

Authors:  D T Fearon
Journal:  J Exp Med       Date:  1980-07-01       Impact factor: 14.307

View more
  3 in total

1.  Studies of phagocytosis in chronic granulomatous disease.

Authors:  T A Gaither; S R Medley; J I Gallin; M M Frank
Journal:  Inflammation       Date:  1987-06       Impact factor: 4.092

Review 2.  Current concepts of hyperinflammation in chronic granulomatous disease.

Authors:  Nikolaus Rieber; Andreas Hector; Taco Kuijpers; Dirk Roos; Dominik Hartl
Journal:  Clin Dev Immunol       Date:  2011-07-25

Review 3.  Hyperimmunoglobulin E syndrome: Genetics, immunopathogenesis, clinical findings, and treatment modalities.

Authors:  Hassan Hashemi; Masoumeh Mohebbi; Shiva Mehravaran; Mehdi Mazloumi; Hamidreza Jahanbani-Ardakani; Seyed-Hossein Abtahi
Journal:  J Res Med Sci       Date:  2017-04-26       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.